What Researchers Did
Researchers reviewed various intravesical treatments for bladder pain syndrome/interstitial cystitis (BPS/IC) to assess their effectiveness.
What They Found
The review found that botulinum neurotoxin A injection, intravesical sodium hyaluronate instillation, and dimethyl sulfoxide (DMSO) instillation were the best-performing treatments. These therapies demonstrated response rates of 79%, 76%, and 75% respectively, and can be effectively used as second-line or third-line options for BPS/IC.
What This Means for Canadian Patients
Canadian patients suffering from bladder pain syndrome/interstitial cystitis may benefit from these intravesical therapies as potential second-line or third-line treatment options. These treatments could offer relief for a disabling chronic condition where current therapies are often off-label.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
The researchers noted that additional high-quality randomized controlled trials are needed to improve the available data on these treatments.